AstraZeneca Signs Deal With China’s CanSino on mRNA Vaccines

The logo of AstraZeneca on medication packages in a pharmacy in London on April 28, 2014. Stefan Wermuth/Reuters

AstraZeneca has signed a messenger RNA (mRNA) vaccines manufacturing deal on Monday with Chinese biopharmaceutical firm CanSino Biologics.

In filings to the Hong Kong (pdf) and Shanghai (pdf) stock exchanges, CanSino said it will manufacture and supply unspecified products and provide related services to AstraZeneca using its mRNA manufacturing platform.